Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis

BackgroundAlthough electronic health interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease is lacking. ObjectiveWe aimed to evaluate the cost-effectiveness and cost-utility of the Telemonitorización de l...

Full description

Bibliographic Details
Main Authors: Del Hoyo, Javier, Nos, Pilar, Bastida, Guillermo, Faubel, Raquel, Muñoz, Diana, Garrido-Marín, Alejandro, Valero-Pérez, Elena, Bejar-Serrano, Sergio, Aguas, Mariam
Format: Article
Language:English
Published: JMIR Publications 2019-09-01
Series:Journal of Medical Internet Research
Online Access:http://www.jmir.org/2019/9/e15505/
_version_ 1818898207418089472
author Del Hoyo, Javier
Nos, Pilar
Bastida, Guillermo
Faubel, Raquel
Muñoz, Diana
Garrido-Marín, Alejandro
Valero-Pérez, Elena
Bejar-Serrano, Sergio
Aguas, Mariam
author_facet Del Hoyo, Javier
Nos, Pilar
Bastida, Guillermo
Faubel, Raquel
Muñoz, Diana
Garrido-Marín, Alejandro
Valero-Pérez, Elena
Bejar-Serrano, Sergio
Aguas, Mariam
author_sort Del Hoyo, Javier
collection DOAJ
description BackgroundAlthough electronic health interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease is lacking. ObjectiveWe aimed to evaluate the cost-effectiveness and cost-utility of the Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn’s Disease and Ulcerative Colitis [TECCU]) Web platform (G_TECCU intervention group) for telemonitoring complex inflammatory bowel disease, compared with standard care (G_control) and nurse-assisted telephone care (G_NT intervention group). MethodsWe analyzed cost-effectiveness from a societal perspective by comparing the 3 follow-up methods used in a previous 24-week randomized controlled trial, conducted at a tertiary university hospital in Spain. Patients with inflammatory bowel disease who initiated immunosuppressants or biologic agents, or both, to control inflammatory activity were recruited consecutively. Data on the effects on disease activity (using clinical indexes) and quality-adjusted life-years (using the EuroQol 5 dimensions questionnaire) were collected. We calculated the costs of health care, equipment, and patients’ productivity and social activity impairment. We compared the mean costs per patient, utilities, and bootstrapped differences. ResultsWe included 63 patients (21 patients per group). TECCU saved €1005 (US $1100) per additional patient in remission compared with G_control (95% CI €–13,518 to 3137; US $–14,798 to 3434), with a 79.96% probability of being more effective at lower costs. Compared with G_NT, TECCU saved €2250 (US $2463) per additional patient in remission (95% CI €–15,363 to 11,086; US $–16,817 to 12,135), and G_NT saved €538 (US $589) compared with G_control (95% CI €–6475 to 5303; US $–7088 to 5805). G_TECCU and G_NT showed an 84% and 67% probability, respectively, of producing a cost saving per additional quality-adjusted life-year (QALY) compared with G_control, considering those simulations that involved negative incremental QALYs as well. ConclusionsThere is a high probability that the TECCU Web platform is more cost-effective than standard and telephone care in the short term. Further research considering larger cohorts and longer time horizons is required. Trial RegistrationClinicalTrials.gov NCT02943538; https://clinicaltrials.gov/ct2/show/NCT02943538 (http://www. webcitation.org/746CRRtDN)
first_indexed 2024-12-19T19:28:24Z
format Article
id doaj.art-ba112d3d85aa4ff5bce53730722aac4b
institution Directory Open Access Journal
issn 1438-8871
language English
last_indexed 2024-12-19T19:28:24Z
publishDate 2019-09-01
publisher JMIR Publications
record_format Article
series Journal of Medical Internet Research
spelling doaj.art-ba112d3d85aa4ff5bce53730722aac4b2022-12-21T20:08:43ZengJMIR PublicationsJournal of Medical Internet Research1438-88712019-09-01219e1550510.2196/15505Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness AnalysisDel Hoyo, JavierNos, PilarBastida, GuillermoFaubel, RaquelMuñoz, DianaGarrido-Marín, AlejandroValero-Pérez, ElenaBejar-Serrano, SergioAguas, MariamBackgroundAlthough electronic health interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease is lacking. ObjectiveWe aimed to evaluate the cost-effectiveness and cost-utility of the Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn’s Disease and Ulcerative Colitis [TECCU]) Web platform (G_TECCU intervention group) for telemonitoring complex inflammatory bowel disease, compared with standard care (G_control) and nurse-assisted telephone care (G_NT intervention group). MethodsWe analyzed cost-effectiveness from a societal perspective by comparing the 3 follow-up methods used in a previous 24-week randomized controlled trial, conducted at a tertiary university hospital in Spain. Patients with inflammatory bowel disease who initiated immunosuppressants or biologic agents, or both, to control inflammatory activity were recruited consecutively. Data on the effects on disease activity (using clinical indexes) and quality-adjusted life-years (using the EuroQol 5 dimensions questionnaire) were collected. We calculated the costs of health care, equipment, and patients’ productivity and social activity impairment. We compared the mean costs per patient, utilities, and bootstrapped differences. ResultsWe included 63 patients (21 patients per group). TECCU saved €1005 (US $1100) per additional patient in remission compared with G_control (95% CI €–13,518 to 3137; US $–14,798 to 3434), with a 79.96% probability of being more effective at lower costs. Compared with G_NT, TECCU saved €2250 (US $2463) per additional patient in remission (95% CI €–15,363 to 11,086; US $–16,817 to 12,135), and G_NT saved €538 (US $589) compared with G_control (95% CI €–6475 to 5303; US $–7088 to 5805). G_TECCU and G_NT showed an 84% and 67% probability, respectively, of producing a cost saving per additional quality-adjusted life-year (QALY) compared with G_control, considering those simulations that involved negative incremental QALYs as well. ConclusionsThere is a high probability that the TECCU Web platform is more cost-effective than standard and telephone care in the short term. Further research considering larger cohorts and longer time horizons is required. Trial RegistrationClinicalTrials.gov NCT02943538; https://clinicaltrials.gov/ct2/show/NCT02943538 (http://www. webcitation.org/746CRRtDN)http://www.jmir.org/2019/9/e15505/
spellingShingle Del Hoyo, Javier
Nos, Pilar
Bastida, Guillermo
Faubel, Raquel
Muñoz, Diana
Garrido-Marín, Alejandro
Valero-Pérez, Elena
Bejar-Serrano, Sergio
Aguas, Mariam
Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
Journal of Medical Internet Research
title Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
title_full Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
title_fullStr Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
title_full_unstemmed Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
title_short Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
title_sort telemonitoring of crohn s disease and ulcerative colitis teccu cost effectiveness analysis
url http://www.jmir.org/2019/9/e15505/
work_keys_str_mv AT delhoyojavier telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT nospilar telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT bastidaguillermo telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT faubelraquel telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT munozdiana telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT garridomarinalejandro telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT valeroperezelena telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT bejarserranosergio telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis
AT aguasmariam telemonitoringofcrohnsdiseaseandulcerativecolitisteccucosteffectivenessanalysis